ANKRD13B is a ubiquitin-binding protein that specifically recognizes Lys-63-linked ubiquitin chains and functions as a molecular adaptor in receptor endocytosis. The protein contains ubiquitin-interacting motifs (UIMs) that bind ubiquitinated EGFR at the plasma membrane, facilitating ligand-activated receptor internalization 1. ANKRD13B acts as a scaffold promoting transient complex formation between activated EGFR and E3 ubiquitin ligases ITCH and RNF11, thereby regulating receptor sorting for lysosomal degradation 1. The protein localizes to early endosomes, late endosomes, and the plasma membrane, where it participates in receptor-mediated endocytosis regulation 1. Clinically, ANKRD13B has emerged as a potential biomarker across multiple cancer types. In colorectal cancer, ANKRD13B was identified as a hub gene with strong predictive performance in distinguishing normal from cancerous tissues and predicting disease progression 2. Similarly, in hepatocellular carcinoma, ANKRD13B was identified as a core prognostic marker through machine learning analyses, with in vitro validation demonstrating its role in promoting cancer cell proliferation, invasion, and migration 3. In clear cell renal cell carcinoma, ANKRD13B showed significant co-expression correlations with TRIM46, an oncogenic protein involved in tumor progression 4. These findings suggest ANKRD13B may represent a therapeutic target for cancer management.